Generic Oncology Drugs Market’s CAGR of 6.3%: Leading Companies to Watch in 2026 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market

How AI and Precision Diagnostics Are Shaping Multiplexed Diagnostic Assays According to a newly published market research report by 24LifeSciences, the global high-density multiplexed diagnostic assays market was valued at USD 1,617 million in 2026 and is projected to reach USD 3,878 million by 2034, growing at a compound annual growth rate (CAGR) of 13.6% during the forecast period. High-density multiplexed diagnostic assays are sophisticated laboratory techniques capable of simultaneously measuring dozens to thousands of analytes from a single, minimal sample volume. These assays represent a paradigm shift in diagnostic capabilities, offering comprehensive profiling that conserves time, reagents, and precious biological samples. Powered by advanced technologies including microarray platforms, bead-based arrays, and next-generation sequencing (NGS), these tools are revolutionizing diagnostics across immunology, oncology, infectious diseases, and biomarker discovery. Their ability to deliver extensive data from one test run is transforming how clinicians and researchers approach complex disease profiling and personalized medicine. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9125/high-density-multiplexed-diagnostic-assays-market

Top 7 Diagnostic Innovations Shaping the Human Cystatin C Assay Kit Industry According to a newly published market research report by 24LifeSciences, global Human Cystatin C Assay Kit market was valued at USD 215 million in 2026 and is projected to reach USD 367 million by 2034, growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period. Human Cystatin C Assay Kits are in-vitro diagnostic tools designed to quantitatively measure the level of Cystatin C, a low molecular weight protein, in human serum or plasma. This biomarker is a crucial and highly sensitive indicator for assessing glomerular filtration rate (GFR), offering a more reliable alternative to traditional creatinine-based tests. Because of its consistent production rate and minimal influence by muscle mass, age, or diet, Cystatin C is increasingly recognized as a superior marker for early detection of renal impairment across diverse patient populations. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9947/human-cystatin-c-assay-kit-market

Non-Sterile Compounding Pharmacy Market Outlook 2025–2032: Size, Trends & Players According to a newly published market research report by 24LifeSciences, global non-sterile compounding pharmacy market is valued at USD 595 million in 2026 and is projected to reach USD 694 million by 2034, growing at a compound annual growth rate (CAGR) of 2.3% during the forecast period. Non-sterile compounding involves the customized preparation of medications for oral, topical, nasal, otic, or rectal administration, tailored to meet specific patient needs unavailable in commercial formulations. This practice requires strict adherence to regulatory standards like USP Chapter <795>, ensuring product integrity, accurate dosing, and patient safety. Its critical role in personalized medicine makes it indispensable for populations requiring unique formulations, including pediatric, geriatric, and patients with allergies or sensitivities to standard drug excipients. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9556/non-sterile-compounding-pharmacy-market

Global Bladder Cancer Therapeutics & Diagnostics Market Growing at a CAGR of 7.5% According to a newly published market research report by 24LifeSciences, global bladder cancer therapeutics and diagnostics market was valued at USD 462 million in 2026 and is projected to reach USD 756 million by 2034, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period. Bladder cancer therapeutics and diagnostics encompass a wide range of products and technologies essential for detecting, diagnosing, and treating malignancies of the bladder. This includes both critical diagnostic tools such as cystoscopy, urine cytology, advanced imaging, and biomarker tests, as well as therapeutic interventions like intravesical therapies, systemic chemotherapy, immunotherapy, and targeted agents. These solutions are vital for managing a disease that ranks as the 6th most commonly diagnosed cancer in men globally, according to the International Agency for Research on Cancer (IARC). Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8974/bladder-cancer-therapeutics-and-diagnostics-market

What Is the Future of the Phoropters and Autorefractors Market? Growth Insights According to a newly published market research report by 24LifeSciences, global Phoropters and Autorefractors market is valued at USD 1.8 billion in 2026 and is projected to reach USD 2.7 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.2% during the forecast period. Phoropters and autorefractors are indispensable diagnostic instruments used in optometric and ophthalmic practices to determine a patient's precise eyeglass prescription. A phoropter is a manual device containing a range of lenses that an eye care professional uses during a subjective refraction test, allowing for fine-tuned adjustments based on patient feedback. In contrast, an autorefractor is an automated computerized instrument that provides an objective, rapid measurement of a person's refractive error, serving as a critical starting point for the prescription process. These devices are fundamental for diagnosing and managing common vision conditions such as myopia, hyperopia, astigmatism, and presbyopia, forming the cornerstone of comprehensive eye examinations worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9993/phoropters-and-autorefractors-market

Top 10 Players Shaping the Global Hepatitis E Diagnostic Tests Market (2026–2034) According to a newly published market research report by 24LifeSciences, global Hepatitis E Diagnostic Tests market is valued at USD 40.1 million in 2026 and is projected to reach USD 47.1 million by 2034, growing at a compound annual growth rate (CAGR) of 2.4% during the forecast period. Hepatitis E diagnostic tests are critical medical tools designed to detect the presence of the Hepatitis E Virus (HEV), an RNA virus responsible for acute liver inflammation. These tests are indispensable for confirming infection, particularly during outbreaks and for high-risk populations such as pregnant women, immunocompromised individuals, and patients with pre-existing liver conditions. The primary diagnostic methodologies include Enzyme-Linked Immunosorbent Assay (ELISA) kits, which identify IgM and IgG antibodies, and advanced molecular techniques like Reverse Transcription-Polymerase Chain Reaction (RT-PCR) tests that detect viral RNA directly, offering high specificity and sensitivity. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9474/hepatitis-e-diagnostic-tests-market

Nanotechnology in Drug Delivery Market to Reach USD 10 Billion by 2034 | Key Trends According to a newly published market research report by 24LifeSciences, global nanotechnology in drug delivery market was valued at USD 4.96 billion in 2026 and is projected to reach USD 10.02 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.8% during the forecast period. Nanotechnology in drug delivery represents a transformative approach in pharmaceutical sciences, focusing on the engineering of materials at the nanoscale (typically 1 to 100 nanometers) to develop advanced systems for transporting therapeutic agents. These innovative platformsincluding nanoparticles, liposomes, dendrimers, and nanocrystalsare engineered to significantly improve drug solubility, enhance bioavailability, enable precise targeted delivery to specific sites such as tumors, and provide controlled release of active compounds. The primary advantage lies in maximizing therapeutic efficacy while simultaneously minimizing systemic side effects, a critical advancement especially for potent chemotherapeutic agents and biologics. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9246/nanotechnology-in-drug-delivery-market

Top 7 Innovations Shaping the Myelodysplastic Syndrome Treatment Landscape According to a newly published market research report by 24LifeSciences, global myelodysplastic syndrome treatment market was valued at USD 1.83 billion in 2026 and is projected to reach USD 3.2 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.1% during the forecast period. Myelodysplastic Syndromes (MDS) are a group of diverse bone marrow disorders characterized by ineffective blood cell production and a high risk of progression to acute myeloid leukemia (AML). The MDS treatment landscape has evolved significantly, moving beyond traditional supportive care to encompass hypomethylating agents (HMAs), immunomodulatory drugs, targeted therapies, and the only potential cure, allogeneic stem cell transplantation. This progression reflects a deeper understanding of the disease's genetic complexity and the urgent need for more effective interventions. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10331/myelodysplastic-syndrome-treatment-market

How Oncology Demand Is Shaping the Doxorubicin Hydrochloride Injection Market According to a newly published market research report by 24LifeSciences, global doxorubicin hydrochloride for injection market was valued at USD 1.2 billion in 2026 and is projected to reach USD 1.7 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period. Doxorubicin hydrochloride, an essential anthracycline chemotherapeutic agent, is a cornerstone in treating a broad spectrum of cancers, including breast cancer, ovarian cancer, lymphomas, and sarcomas. Its mechanism of action involves intercalating DNA and inhibiting topoisomerase II, thereby disrupting DNA replication and RNA synthesis in rapidly dividing cancer cells. Available primarily in 10mg and 50mg vials, its established efficacy in numerous chemotherapy protocols continues to underpin its critical role in oncology. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10567/doxorubicin-hydrochloride-for-injection-market

Global RA Drugs Market Size, Share & Forecast to 2032 | Key Players According to a newly published market research report by 24LifeSciences, global rheumatoid arthritis (RA) drugs market was valued at USD 60.2 billion in 2026 and is projected to reach USD 78.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.3% during the forecast period. Rheumatoid Arthritis (RA) drugs represent the cornerstone of treatment for a chronic autoimmune disorder characterized by persistent joint inflammation, pain, and progressive disability. The therapeutic landscape has evolved significantly beyond symptomatic relief with NSAIDs and corticosteroids to include advanced Disease-Modifying Antirheumatic Drugs (DMARDs), biologic agents targeting specific immune pathways, and innovative Janus kinase (JAK) inhibitors. These treatments aim to achieve disease remission, prevent structural joint damage, and improve long-term patient outcomes, making them essential in modern rheumatology practice. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9176/rheumatoid-arthritis-ra-drugs-market

Global Artificial Intelligence Pathology Diagnosis Market: Key Trends & Opportunities According to a newly published market research report by 24LifeSciences, global inflammatory bowel disease treatment market is valued at USD 13.03 billion in 2026 and is projected to reach USD 15.41 billion by 2034, growing at a compound annual growth rate (CAGR) of 2.5% during the forecast period. Inflammatory Bowel Disease (IBD) treatments encompass a comprehensive range of therapeutics designed to manage chronic inflammatory conditions primarily affecting the gastrointestinal tract, including Crohn's disease and ulcerative colitis. These treatments are meticulously developed to induce and maintain remission, alleviate debilitating symptoms, and improve patients' quality of life. The market features several key drug classes: aminosalicylates, which serve as effective first-line therapy for mild-to-moderate cases; TNF inhibitors, a class of advanced biologics that precisely target the tumor necrosis factor-alpha pathway; corticosteroids for their potent anti-inflammatory effects during acute flare-ups; and immunomodulators, which work by modifying the abnormal immune response characteristic of these conditions. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9181/inflammatory-bowel-disease-treatment-market